CN Patent

CN116916934A — 用于治疗自身免疫性病症的新型治疗方案

Assigned to Merck Patent GmbH · Expires 2023-10-20 · 3y expired

What this patent protects

本发明涉及用于治疗自身免疫性病症的新型治疗方案。所述新型治疗方案优选给患者提供具有有利的安全性概况和/或高生活质量的自身免疫性病症的有效治疗。优选地，所述新型治疗方案给受到感染风险威胁的患者提供有利的利益风险比。

USPTO Abstract

本发明涉及用于治疗自身免疫性病症的新型治疗方案。所述新型治疗方案优选给患者提供具有有利的安全性概况和/或高生活质量的自身免疫性病症的有效治疗。优选地，所述新型治疗方案给受到感染风险威胁的患者提供有利的利益风险比。

Drugs covered by this patent

Patent Metadata

Patent number
CN116916934A
Jurisdiction
CN
Classification
—
Expires
2023-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.